Literature DB >> 21822701

Commentary on "expression of dopamine 2 receptor subtypes mRNA in clinically nonfunctioning pituitary adenomas".

Andrea Salmaggi1, Sandro Lodrini.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21822701     DOI： 10.1007/s10072-011-0705-2

Source DB:  PubMed          Journal:  Neurol Sci        ISSN： 1590-1874            Impact factor:   3.307


× No keyword cloud information.
  4 in total

1.  Expression of dopamine 2 receptor subtype mRNA in clinically nonfunctioning pituitary adenomas.

Authors:  Zhipeng Su; Chengde Wang; Jinsen Wu; Xiaolong Jiang; Yunxiang Chen; Yong Chen; Weiming Zheng; Qichuan Zhuge; Zhebao Wu; Yanjun Zeng
Journal:  Neurol Sci       Date:  2011-07-12       Impact factor: 3.307

2.  Dopamine 2 receptor expression in various pathological types of clinically non-functioning pituitary adenomas.

Authors:  Filip Gabalec; Martin Beranek; David Netuka; Vaclav Masopust; Jiri Nahlovsky; Tomas Cesak; Josef Marek; Jan Cap
Journal:  Pituitary       Date:  2012-06       Impact factor: 4.107

Review 3.  Non-functioning pituitary adenomas.

Authors:  Yona Greenman; Naftali Stern
Journal:  Best Pract Res Clin Endocrinol Metab       Date:  2009-10       Impact factor: 4.690

4.  The dopamine-somatostatin chimeric compound BIM-23A760 exerts antiproliferative and cytotoxic effects in human non-functioning pituitary tumors by activating ERK1/2 and p38 pathways.

Authors:  Erika Peverelli; Luca Olgiati; Marco Locatelli; Paolo Magni; Marco Faustini Fustini; Giorgio Frank; Giovanna Mantovani; Paolo Beck-Peccoz; Anna Spada; Andrea Lania
Journal:  Cancer Lett       Date:  2009-07-19       Impact factor: 8.679
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.